Literature DB >> 23099129

Insomnia.

Maryann C Deak1, John W Winkelman.   

Abstract

Insomnia is a common disorder, with individual and societal consequences. Advances have been made in the understanding of insomnia and its treatment options. However, cognitive behavioral therapy and Food and Drug Administration-approved pharmacologic therapies have limitations, the former primarily involving access and the latter involving potential side effects. Further research is needed to optimize management strategies.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23099129     DOI: 10.1016/j.ncl.2012.08.012

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  2 in total

1.  A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance.

Authors:  Sandy A Furey; Steven G Hull; Mark T Leibowitz; Shyamalie Jayawardena; Thomas Roth
Journal:  J Clin Sleep Med       Date:  2014-10-15       Impact factor: 4.062

2.  Comparison of the Use of Hypnotic in Psychiatric Patients with Insomnia at the Mental Health Centre Prolet in Skopje.

Authors:  Viktor Isjanovski; Igor Isjanovski
Journal:  Open Access Maced J Med Sci       Date:  2019-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.